Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines that modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/07/25 | $300,000,000 | Series A |
ARCH Venture Partners Perceptive Advisors  Sequoia Heritage | undisclosed |
